Neurocrine Biosciences, Inc. (NBIX): Price and Financial Metrics

Neurocrine Biosciences, Inc. (NBIX): $97.05

1.36 (+1.42%)

POWR Rating

Component Grades














  • Quality is the dimension where NBIX ranks best; there it ranks ahead of 96.4% of US stocks.
  • The strongest trend for NBIX is in Value, which has been heading up over the past 179 days.
  • NBIX ranks lowest in Momentum; there it ranks in the 32nd percentile.

NBIX Stock Summary

  • NBIX has a higher market value than 83.51% of US stocks; more precisely, its current market capitalization is $9,190,339,732.
  • With a price/earnings ratio of 59.48, NEUROCRINE BIOSCIENCES INC P/E ratio is greater than that of about 91.21% of stocks in our set with positive earnings.
  • With a year-over-year growth in debt of -40.3%, NEUROCRINE BIOSCIENCES INC's debt growth rate surpasses only 7.12% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to NEUROCRINE BIOSCIENCES INC, a group of peers worth examining would be MRAM, PDEX, NSPR, SONO, and CLPT.
  • Visit NBIX's SEC page to see the company's official filings. To visit the company's web site, go to

NBIX Valuation Summary

  • NBIX's price/sales ratio is 6.1; this is 221.05% higher than that of the median Healthcare stock.
  • NBIX's EV/EBIT ratio has moved up 55.2 over the prior 243 months.

Below are key valuation metrics over time for NBIX.

Stock Date P/S P/B P/E EV/EBIT
NBIX 2023-03-17 6.1 5.3 58.9 41.2
NBIX 2023-03-16 6.1 5.3 58.9 41.2
NBIX 2023-03-15 6.1 5.3 58.8 41.1
NBIX 2023-03-14 6.2 5.4 59.7 41.7
NBIX 2023-03-13 6.1 5.3 59.0 41.3
NBIX 2023-03-10 6.2 5.4 59.9 41.9

NBIX Growth Metrics

    Its 3 year price growth rate is now at 15.15%.
  • The year over year net cashflow from operations growth rate now stands at -53.64%.
  • Its 3 year net cashflow from operations growth rate is now at 370.41%.
Over the past 52 months, NBIX's revenue has gone up $1,074,435,000.

The table below shows NBIX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 1,488.7 339.4 154.5
2022-09-30 1,388.7 200.6 58.2
2022-06-30 1,296.8 163.6 12.2
2022-03-31 1,207.5 128.7 71.4
2021-12-31 1,133.5 256.5 89.6
2021-09-30 1,069.4 341.2 444.8

NBIX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NBIX has a Quality Grade of B, ranking ahead of 78.08% of graded US stocks.
  • NBIX's asset turnover comes in at 0.566 -- ranking 66th of 682 Pharmaceutical Products stocks.
  • LGND, MNKD, and MRK are the stocks whose asset turnover ratios are most correlated with NBIX.

The table below shows NBIX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.566 0.988 0.102
2021-06-30 0.586 0.989 0.063
2021-03-31 0.634 0.990 0.092
2020-12-31 0.684 0.990 0.105
2020-09-30 0.733 0.991 0.118
2020-06-30 0.750 0.991 0.199

NBIX Price Target

For more insight on analysts targets of NBIX, see our NBIX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $122.19 Average Broker Recommendation 1.52 (Moderate Buy)

NBIX Stock Price Chart Interactive Chart >

Price chart for NBIX

NBIX Price/Volume Stats

Current price $97.05 52-week high $129.29
Prev. close $95.69 52-week low $75.25
Day low $95.02 Volume 801,600
Day high $97.48 Avg. volume 839,526
50-day MA $102.91 Dividend yield N/A
200-day MA $106.79 Market Cap 9.37B

Neurocrine Biosciences, Inc. (NBIX) Company Bio

Neurocrine Biosciences discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company was founded in 1992 and is based in San Diego, California.

NBIX Latest News Stream

Event/Time News Detail
Loading, please wait...

NBIX Latest Social Stream

Loading social stream, please wait...

View Full NBIX Social Stream

Latest NBIX News From Around the Web

Below are the latest news stories about NEUROCRINE BIOSCIENCES INC that investors may wish to consider to help them evaluate NBIX as an investment opportunity.

Neurocrine Biosciences to Present at the Stifel 2023 CNS Days

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 2023 CNS Days at 12:30 p.m. Eastern Time on Tuesday, March 28, 2023. Eiry Roberts, Chief Medical Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will participate at the conference.

Yahoo | March 21, 2023

3 Growth Stocks That Could Disrupt the Healthcare Industry

These healthcare growth stocks will continue to provide steady and consistent returns, rewarding smart investors over time.

Alex Sirois on InvestorPlace | March 13, 2023

Neurocrine Biosciences Announces Results from the Real-World RE-KINECT™ Study Published in the Journal of Patient-Reported Outcomes Demonstrating the Effects of Possible Tardive Dyskinesia (TD) on Patient Health and Social Functioning

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that new data from RE-KINECT™, the largest real-world, observational, multicenter study of antipsychotic-treated patients with possible tardive dyskinesia (TD), was published in the Journal of Patient-Reported Outcomes.1 The analysis assessed the effects of possible TD, defined as clinician-confirmed presence of abnormal involuntary movements, on patient health and social functioning. It demonstrated that it's important for clinicians t

Yahoo | March 9, 2023

Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsule Contents via Soft Foods or Feeding Tube at AMDA - PALTC 2023 Annual Conference

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data from three in vitro dissolution studies exploring the dissolution performance of INGREZZA® (valbenazine) capsule contents through soft foods or a gastrostomy (G-tube) feeding tube. The data (Poster #IND03, Valbenazine Capsule Contents for Potential Administration via Soft Food/Feeding Tube) will be presented at AMDA – The Society for Post-Acute and Long-Term Care Medicine's PALTC23 Annual Conference being held March

Yahoo | March 9, 2023

Neurocrine Biosciences to Participate at Investor Conferences in March

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the Barclays Global Healthcare Conference at 10:45 a.m. Eastern Time on Wednesday, March 15 2023 in Miami. Neurocrine Biosciences will participate in the Jefferies Biotech on the Bay Summit on Thursday, March 16 2023 in Miami.

Yahoo | March 8, 2023

Read More 'NBIX' Stories Here

NBIX Price Returns

1-mo -5.27%
3-mo N/A
6-mo -4.25%
1-year 3.55%
3-year 4.90%
5-year 19.40%
YTD -18.75%
2022 40.24%
2021 -11.14%
2020 -10.83%
2019 50.53%
2018 -7.96%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7733 seconds.